EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human cytomegalovirus seropositivity and its influence on oral rotavirus vaccine immunogenicity: a specific concern for HIV-exposed-uninfected infants

Natasha Laban iD, Samuel Bosomprah, Roma Chilengi, Michelo Simuyandi, Caroline Chisenga, Harriet Ng'ombe, Kalo Musukuma-Chifulo, Martin Goodier

Clinical and Experimental Immunology · 20.06.2024 · 217 (1) · 99-108

DOI: 10.1093/cei/uxae029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 28.03.2024. Verfasst von Natasha Laban und 7 weiteren Autor:innen. Beteiligte Einrichtung: Enteric Disease and Vaccine Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Hauptthemen laut MEDLINE: Rotavirus Vaccines, Cytomegalovirus, Antibodies, Viral, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Second European and Developing Countries Clinical Trials Partnership, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral rotavirus vaccines demonstrate diminished immunogenicity in low-income settings where human cytomegalovirus infection is acquired early in childhood and modulates immunity. We hypothesized that human cytomegalovirus infection around the time of vaccination may influence immunogenicity. We measured plasma human cytomegalovirus-specific immunoglobulin M antibodies in rotavirus vaccinated infants from 6 weeks to 12 months old and compared rotavirus immunoglobulin A antibody titers between human cytomegalovirus seropositive and seronegative infants. There was no evidence of an association between human cytomegalovirus serostatus at 9 months and rotavirus-specific antibody titers at 12 months (geometric mean ratio 1.01, 95% CI: 0.70, 1.45; P = 0.976) or fold-increase in RV-IgA titer between 9 and 12 months (risk ratio 0.999, 95%CI: 0.66, 1.52; P = 0.995) overall. However, HIV-exposed-uninfected infants who were seropositive for human cytomegalovirus at 9 months old had a 63% reduction in rotavirus antibody geometric mean titers at 12 months compared to HIV-exposed-uninfected infants who were seronegative for human cytomegalovirus (geometric mean ratio 0.37, 95% CI: 0.17, 0.77; P = 0.008). While the broader implications of human cytomegalovirus infections on oral rotavirus vaccine response might be limited in the general infant population, the potential impact in the HIV-exposed-uninfected infants cannot be overlooked. This study highlights the complexity of immunological responses and the need for targeted interventions to ensure oral rotavirus vaccine efficacy, especially in vulnerable subpopulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rotavirus VaccinesCytomegalovirusAntibodies, ViralCytomegalovirus InfectionsHIV InfectionsRotavirus InfectionsHumansInfantMaleFemaleImmunogenicity, VaccineRotavirusImmunoglobulin AAdministration, OralImmunoglobulin MVaccination

Stichwörter der Autor:innen

Zambiaantibodyhuman cytomegalovirusrotavirusvaccine

Substanzen

Rotavirus VaccinesAntibodies, ViralImmunoglobulin AImmunoglobulin M

Autor:innen und Institutionen

  • Enteric Disease and Vaccine Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
  • Department of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.
  • Flow Cytometry and Immunology Facility, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Banjul, The Gambia.

ORCID-Profile: Natasha Laban

Förderung

  • Wellcome Trust
  • Second European and Developing Countries Clinical Trials Partnership
  • European Union

Zitieren

APA

Laban, N., Bosomprah, S., Chilengi, R., Simuyandi, M., Chisenga, C., Ng'ombe, H., Musukuma-Chifulo, K., & Goodier, M. (2024). Human cytomegalovirus seropositivity and its influence on oral rotavirus vaccine immunogenicity: a specific concern for HIV-exposed-uninfected infants. Clinical and Experimental Immunology, 217(1), 99-108. https://doi.org/10.1093/cei/uxae029

Vancouver

Laban N, Bosomprah S, Chilengi R, Simuyandi M, Chisenga C, Ng'ombe H, et al. Human cytomegalovirus seropositivity and its influence on oral rotavirus vaccine immunogenicity: a specific concern for HIV-exposed-uninfected infants. Clinical and Experimental Immunology. 2024;217(1):99-108. doi:10.1093/cei/uxae029

BibTeX
@article{Laban2024,
  author = {Laban, Natasha and Bosomprah, Samuel and Chilengi, Roma and Simuyandi, Michelo and Chisenga, Caroline and Ng'ombe, Harriet and Musukuma-Chifulo, Kalo and Goodier, Martin},
  title = {Human cytomegalovirus seropositivity and its influence on oral rotavirus vaccine immunogenicity: a specific concern for HIV-exposed-uninfected infants},
  journal = {Clinical and Experimental Immunology},
  year = {2024},
  volume = {217},
  number = {1},
  pages = {99--108},
  doi = {10.1093/cei/uxae029}
}
Kostenlos starten →